Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Differences between homoeopathic immunotherapy trials by Lewith et al and Reilly et al
|
Lewith et al1 |
Reilly et al2 |
Possible implications |
|
|
Research context and stage of inquiry |
1st pilot of new design for HIT in asthma |
One of a series of 4 trials using HIT and allergy as a model |
Lewith et al inquiry needs a second phase |
|
Aims |
Evaluate efficacy of HIT in asthma |
Evaluate placebo hypothesis of homoeopathy |
Different questions |
|
Clinical context |
Primary care patients (38 practices) |
Specialist care patients (one centre for investigation of respiratory disease) |
Different patient group, different illness severity, different context effects |
|
Design bias |
Effectiveness—long clinical observation in the real world of primary care application |
Efficacy—highly focused, intense, short observation to ensure internal validity |
Lewith et al showed effectiveness but could not show efficacy; Reilly et al is the opposite |
|
Conventional diagnosis of asthma |
Clinic criteria, symptoms, and simple respiratory tests |
As for Lewith et al’s trial plus laboratory confirmation with histamine provocation testing |
Lewith et al’s trial OK for an effectiveness study but Reilly et al’s trial had more accurate selection for an efficacy study |
|
Basis of the homoeopathic diagnosis for the HIT prescription |
Conventional practitioners’ decisions |
Homoeopathic expert with 15 years’ experience of using HIT. Case conference for every case; respiratory and homoeopathic physicians able to bar entry to study |
Reilly et al’s trial had more accurate prescribing; expert decided in cases of ambiguity–for example, when skin reaction weal for house dust mite is equal to a competing allergen |
|
Treatment regimen and observation period |
Three doses over 24 hours; no repetition over next 16 weeks |
Three doses over 24 hours, observed for 4 weeks. In optional 4 week extension period patients given repeat doses at 4 weeks (that is, usual clinical practice) |
Likely inadequate treatment regimen in Lewith et al’s trial. Data at 4 weeks after randomisation should be explored |
|
Baseline data |
Off placebo |
On placebo |
Radically different context effects and baseline |
|
Data collection |
Discontinuous data |
Continuous data |
Unknown impact; patient liable to "reset" to recent baseline after a break ("poor memory of pain") |
|
Seasonal effects in exposure to house dust mite |
Recruitment timing begins 5 months before Reilly et al’s trial and lasts for 30-32 weeks. Wide geographical spread? |
After February and restricted to 4 weeks. Patients from restricted geographic zone |
Reilly et al’s trial has more even exposure; avoids winter peak of house dust mites as HIT will be less effective when seasonal challenge is maximal. May have avoided aggravations |
|
Outcome measures |
"Wider"; discontinuous; visual analogue scale labelled about asthma, different from that in Reilly et al’s study |
"Focused; continuous; visual analogue scale worded differently from Lewith et al’s study ("Overall today I felt ¼") |
Different, so comparison problematic. All 4 HIT trials by Reilly and Taylor et al kept the wording steady |
|
Blinding |
A/B labelling, with research nurse and patient recording this |
Double coded individualised numbering |
Possibility in Lewith et al’s trial of researchers developing and transmitting conscious and unconscious attitudes |
|
Study power and risk of false negative result (type II error) |
Pilot study with best guess power calculation. Underpowered. High placebo response so high risk of a false negative result. No post hoc power calculation |
Based on previous trial in the series. Underpowered yet shows a positive result, so no risk of a false negative result |
Lewith et al’s trial may have false negative result |
|
Outcome |
Good result in both groups. Shows effectiveness, not efficacy, against large non-specific placebo clinical gain. Groups showed different response patterns–possible aggravations mixed with improvements |
Good result only with active treatment. Apparently poorer placebo response |
Placebo enhanced in Lewith et al’s trial. Placebo run-in qualification period in Reilly et al’s trial screened out and corrected for initial placebo effects, increasing power of the study |
HIT = Homoeopathic immunotherapy. VAS = Visual analogue scale.